Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate taste preferences for alcohol during an intravenous infusion of the naturally occurring hormone fibroblast growth factor-21 (FGF21) and placebo (i.e. saline), respectively, in 20 healthy subjects. Secondary endpoints are to evaluate the effects of exogenous FGF21 (compared to placebo) on resting energy expenditure, preference for salt, sour and bitter taste qualities, sensations of hunger, thirst, appetite, satiety, headache and nausea, and makers of glucose metabolism (e.g. plasma/serum concentrations of glucose, C-peptide, insulin and glucagon).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04232033
Study type Interventional
Source University Hospital, Gentofte, Copenhagen
Contact
Status Active, not recruiting
Phase N/A
Start date May 1, 2021
Completion date December 31, 2023